Compare American International Group Inc (AIG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs TG Therapeutics Inc — how do they compare? American International Group Inc trades at $76.02 (market cap $40.42B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: American International Group Inc is far larger — about 5.3× TG Therapeutics Inc's market cap, and American International Group Inc pays a 2.59% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AIG | TGTX | |
|---|---|---|
Market Cap | $40.42B | $7.64B |
Sector | Financials | Health |
52-Week High | $86.59 | $59.06 |
52-Week Low | $71.89 | $26.94 |
Enterprise Value | $48.06B | $7.84B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIG trades at $76.33, down 1.65% on the day, with a bearish technical signal and neutral oscillators. The company shows strong earnings momentum with three consecutive quarterly beats (Q4 2025: $1.96 vs $1.90 expected, Q1 2026: $2.11 vs $1.89, Q2 2026: $2.00 vs $1.92) and maintains a 11.12% net income margin. Recent news highlights CEO Eric Anderson discussing geopolitical opportunities and strong Q2 results with 10% adjusted EPS growth.
AIG presents a mixed outlook with solid fundamentals and earnings consistency offset by bearish technicals. The 12-month consensus price target of $89.00 suggests 16.6% upside potential, supported by 39% analyst buy ratings. Key risks include competitive pricing pressure in North American property insurance and market volatility. The stock's current valuation at 14.11 P/E appears reasonable given earnings growth trajectory.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
